of

Sheet

Examiner Signature

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE cond to a collection of information unless it contains a valid OMB control number. Under the Paperwork Reduction Act of 1995. Complete if Known Substitute for form 1449A/PTO 10/774,697 Application Number INFORMATION DISCLOSURE Filing Date February 10, 2004 STATEMENT BY APPLICANT Richard A. COUCH et al. First Named Inventor 1015-1614 **Group Art Unit** (use as many sheets as necessary) Unassigned LESIJE ROYDS Examiner Name

Attorney Docket Number

PHARMA-0148

25 May 2005

	U.S. PATENT DOCUMENTS									
Examiner Initials *	Cite No.1	U.S. Patent Document Kind Code ² Number (if known)		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document					
LAR	A1	2002/0058061 A1		Kamal K. MIDHA et al.	05/16/2002					
			-							
			-							
			-							
		******	1							
			 							
			-}							

			F	OREIGN P	ATENT DOCUMENTS			
		Foreign Patent Document			·	Date of Publication of	Pages, Columns, Lines, Where Relevant	
Examiner Initials*	Cite No.1	Office ³	Number ⁴	Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	T⁵
LAR	B1	wo	2002/039998 A3		PCT	05/23/2002		
LAR	B2	wo	00/23055		PCT	04/27/2000		
LAR	В3	wo	03/092661 A1	-	PCT	11/13/2003		
LAR	B4	wo	03/072105 A1		PCT	09/04/2003		
		J.						

EXAMINER: Initial if pereioc considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered include copy of this form with no xt dommunication to applicant.

Date

Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Unique citation designation number. 2 See attached sinds of U.S. Patent Documents. 3 Enter Office that Issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST, 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.

SEP 1 3 2004 (2) Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

Complete if Known

10/774,697

ter the Paperwork Reduction Act of 1995, not some sequired to respond to a collection of information unless it contains a valid CMB control number

Application Number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Filing Date
February 10, 2004
First Named Inventor
Richard A. COUCH et al.

Group Art Unit
Examiner Name
February 10, 2004
Richard A. COUCH et al.

Unessigned LESUE ROYDS

Attorney Docket Number PHARMA-0148

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ2
LAR	C1	L. EUGENE ARNOLD et al., Levoamphetamine and Dextroamphetamine: Comparative Efficacy in the Hyperkinetic Syndrome, Assessment by Target Symptoms, Arch Gen Psychiat, Vol. 27, December 1972, pages 816-822	
LAR	C2	L. EUGENE ARNOLD et al., Levoamphetamine and Dextroamphetamine: Differential Effect on Aggression and Hyperkinesis in Children and Dogs, Am J Psychiatry 130:2, February 1973, pages 165-170	
LAR	СЗ	SIMON J. TULLOCH, et al., SLI381 (Adderall XR), a Two-Component, Extended-Release Formulation of Mixed Amphetamine Salts: Bioavailability of Three Test Formulations and Comparison of Fasted, Fed, and Sprinkled Administration, Pharmacotheraphy, Vol. 22, Number 11, 2002, pages 1405-1415	
LAR	C4	KENNERLY S. PATRICK et al., Pharmacology of Methylphenidate, Amphetamine Enantiomers and Pemoline in Attention-Deficit Hyperactivity Disorder, Human Psychopharmacology, Vol. 12, pages 527-546 (1997)	
	ļ		
			-
	l .		

Examiner Signature Date Considered 25 May 2005

EXAMINER: Initial Melevice considered, whether or toot citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 10/31/2002. OMB 0651-0031* S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE spond to a collection of information unless it contains a valid OMB control number. Under the Paperwork Reduction Act of 199

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

MARI	Complete if Known			
Application Number	10/774,697			
Filing Date	February 10, 2004			
First Named Inventor	Richard A. COUCH et al.			
Group Art Unit	1015 1614			
Examiner Name	Unknown LESLIEROYDS			
Attorney Docket Number	PHARMA-0148			

U.S. PATENT DOCUMENTS									
Examiner Initials *	Cite No.1	U.S. Patent Documer Number	nt Kind Code ² (<i>if known</i>)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY				
LAR	1	6,605,300	B1	Beth A. Burnside et al.	08-12-2003				
				· · · · · · · · · · · · · · · · · · ·					
<u> </u>				· · · · · · · · · · · · · · · · · ·					
		•							
				•					
		*							

	FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Foreign Patent Document				Date of Publication of	Pages, Columns, Lines,		
		Office ³	Number ⁴	Kind Code ⁵ (if known)	Name of Patentee or Applican of Cited Document		Where Relevant Passages or Relevant Figures Appear	T ⁶	
	<u> </u>	l							
				· · · · ·					
						•			
					·				
			(N)						
	Examiner Signature Date Considered 25 May 2005								

EXAMINER: Initial of reference considered, whicher or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent occurrents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.

Please type a plus sign (+) inside this box

APR 0 1 2005

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0851-0031

Approved for use through 10/31/2002. OMB 0851-0031

By Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required Respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

Sheet

Examiner

Signature

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of

Complete if Known

Application Number 10/774,697

Filing Date February 10, 2004

First Named Inventor Richard A. COUCH et al.

Group Art Unit 1645 | | | | | |

Examiner Name Unknown LESUE ROY DS

Attorney Docket Number PHARMA-0148

		NON PATENT LITERATURE DOCUMENTS	· .
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
LAR	2	Psychopharmacology 50, 171-175 (1976), Sleep: Effects of <i>d</i> - and <i>I</i> -Amphetamine in Man and in Rat, Emest Hartmann et al.	
LAR	3	The Journal of Pharmacology and Experimental Therapeutics, Vol. 194, No. 1, Amphetamine: Evaluation of d- And I-Isomers As Releasing Agents And Uptake Inhibitors For ³ H-Dopamine and ³ H-Norepinephrine In Slices Of Rat Neostraitum And Cerebral Cortex, Richard E. Heikkila et al., pages 47-56.	
LAR		Biochemical Pharmacology, Vol. 25, pp. 447-451, Effects Of The <i>d</i> - And <i>I</i> -Isomers Of Amphetamine On Uptake, Release And Catabolism Of Norepinephrine, Dopamine And 5-Hydroxytryptamine In Several Regions Of Rat Brain, John C. Holmes et al. / (4 746)	
· · · · · · · · · · · · · · · ·			
	-		
		// (X(I))	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date

Considered

25 May 2005

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.